LegoChem Biosciences Inc Total Assets
LegoChem Biosciences Inc total assets. Based on the latest financial reports, LegoChem Biosciences Inc (141080) holds total assets worth ₩652.93 Billion KRW (≈ $442.48 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 141080 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of LegoChem Biosciences Inc (2014–2025)
Total assets of LegoChem Biosciences Inc from 2014 to 2025. This chart illustrates how LegoChem Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See LegoChem Biosciences Inc share price for real-time trading data and today's change.
LegoChem Biosciences Inc - Asset Composition Analysis
LegoChem Biosciences Inc Total Assets Breakdown (December 2025)
LegoChem Biosciences Inc total assets breakdown as of December 2025. LegoChem Biosciences Inc's total assets of ₩652.93 Billion consist of 74.3% current assets and 25.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 14.1% |
| Accounts Receivable | ₩11.76 Billion | 1.7% |
| Inventory | ₩110.04 Million | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩88.40 Billion | 12.6% |
| Goodwill | ₩16.08 Billion | 2.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how LegoChem Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 141080 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LegoChem Biosciences Inc's current assets represent 74.3% of total assets in 2025, a decrease from 90.7% in 2014.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, up from 4.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
LegoChem Biosciences Inc Competitors by Total Assets
Key competitors of LegoChem Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
LegoChem Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.12 | 5.32 | 5.73 |
| Quick Ratio | 10.12 | 5.32 | 5.71 |
| Cash Ratio | 0.00 | 0.26 | 1.27 |
| Working Capital | ₩432.53 Billion | ₩437.57 Billion | ₩52.45 Billion |
LegoChem Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between LegoChem Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.52 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | ₩701.81 Billion |
| Market Capitalization | $1.48 Billion USD |
Valuation Analysis
Below Book Valuation: The market values LegoChem Biosciences Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LegoChem Biosciences Inc's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LegoChem Biosciences Inc (2014–2025)
The table below shows the annual total assets of LegoChem Biosciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩701.81 Billion ≈ $475.61 Million |
-4.95% |
| 2024-12-31 | ₩738.38 Billion ≈ $500.39 Million |
+289.64% |
| 2023-12-31 | ₩189.50 Billion ≈ $128.42 Million |
-24.96% |
| 2022-12-31 | ₩252.53 Billion ≈ $171.14 Million |
-13.88% |
| 2021-12-31 | ₩293.23 Billion ≈ $198.72 Million |
+115.75% |
| 2020-12-31 | ₩135.91 Billion ≈ $92.11 Million |
-3.93% |
| 2019-12-31 | ₩141.48 Billion ≈ $95.88 Million |
+16.26% |
| 2018-12-31 | ₩121.69 Billion ≈ $82.47 Million |
+47.97% |
| 2017-12-31 | ₩82.24 Billion ≈ $55.73 Million |
-8.17% |
| 2016-12-31 | ₩89.55 Billion ≈ $60.69 Million |
+30.84% |
| 2015-12-31 | ₩68.44 Billion ≈ $46.38 Million |
+102.75% |
| 2014-12-31 | ₩33.76 Billion ≈ $22.88 Million |
-- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more